DK3923973T3 - Langtidsvirkende g-csf til forebyggelse af neutropeni eller reduktion af varigheden af neutropeni - Google Patents

Langtidsvirkende g-csf til forebyggelse af neutropeni eller reduktion af varigheden af neutropeni Download PDF

Info

Publication number
DK3923973T3
DK3923973T3 DK20702699.8T DK20702699T DK3923973T3 DK 3923973 T3 DK3923973 T3 DK 3923973T3 DK 20702699 T DK20702699 T DK 20702699T DK 3923973 T3 DK3923973 T3 DK 3923973T3
Authority
DK
Denmark
Prior art keywords
neutropenai
neutropeania
csf
prevention
duration
Prior art date
Application number
DK20702699.8T
Other languages
English (en)
Inventor
Senem Ertan-Ahmed
Adem Sahin
Hatice Oncel
Onur Pinarbasli
Nagehan Sarracoglu
Original Assignee
Ilkogen Ilac Sanayi Ve Ticaret A S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ilkogen Ilac Sanayi Ve Ticaret A S filed Critical Ilkogen Ilac Sanayi Ve Ticaret A S
Application granted granted Critical
Publication of DK3923973T3 publication Critical patent/DK3923973T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A61K47/6813—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin the drug being a peptidic cytokine, e.g. an interleukin or interferon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/53—Colony-stimulating factor [CSF]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
DK20702699.8T 2019-02-13 2020-01-21 Langtidsvirkende g-csf til forebyggelse af neutropeni eller reduktion af varigheden af neutropeni DK3923973T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962804988P 2019-02-13 2019-02-13
PCT/IB2020/050447 WO2020165664A1 (en) 2019-02-13 2020-01-21 A long-acting g-csf for preventing neutropenia or reducing duration of neutropenia

Publications (1)

Publication Number Publication Date
DK3923973T3 true DK3923973T3 (da) 2023-04-24

Family

ID=69375655

Family Applications (1)

Application Number Title Priority Date Filing Date
DK20702699.8T DK3923973T3 (da) 2019-02-13 2020-01-21 Langtidsvirkende g-csf til forebyggelse af neutropeni eller reduktion af varigheden af neutropeni

Country Status (10)

Country Link
US (1) US11813310B2 (da)
EP (1) EP3923973B1 (da)
KR (1) KR20210127215A (da)
AU (1) AU2020220651A1 (da)
BR (1) BR112021015428A2 (da)
CA (1) CA3130032C (da)
DK (1) DK3923973T3 (da)
EA (1) EA202192241A1 (da)
ES (1) ES2943312T3 (da)
WO (1) WO2020165664A1 (da)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012044921A1 (en) 2010-10-01 2012-04-05 St. Jude Children's Research Hospital Methods and compositions for typing molecular subgroups of medulloblastoma

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8504099D0 (en) 1985-02-18 1985-03-20 Wellcome Found Physiologically active substances
US5214132A (en) 1986-12-23 1993-05-25 Kyowa Hakko Kogyo Co., Ltd. Polypeptide derivatives of human granulocyte colony stimulating factor
US6797493B2 (en) * 2001-10-01 2004-09-28 Lee-Hwei K. Sun Fc fusion proteins of human granulocyte colony-stimulating factor with increased biological activities
KR101380732B1 (ko) 2007-05-30 2014-04-10 포항공과대학교 산학협력단 면역글로불린 융합 단백질
RU2519031C1 (ru) * 2010-01-19 2014-06-10 Ханми Сайенс Ко., Лтд. Жидкие препаративные формы для длительно действующего конъюгата g-csf
CN102380090A (zh) * 2010-08-31 2012-03-21 健能隆医药技术（上海）有限公司 G-csf二聚体在治疗嗜中性粒细胞减少症中的应用
US20160362473A1 (en) * 2015-06-12 2016-12-15 Ubi Pharma Inc Immunoglobulin fusion proteins and uses thereof
EP3773468A2 (en) 2018-05-04 2021-02-17 Ilkogen Ilaç Sanayi ve Ticaret A.S. Stable hybrid fc fusion g-csf formulation

Also Published As

Publication number Publication date
US11813310B2 (en) 2023-11-14
US20200255842A1 (en) 2020-08-13
ES2943312T3 (es) 2023-06-12
CA3130032C (en) 2024-01-16
CA3130032A1 (en) 2020-08-20
EP3923973B1 (en) 2023-02-01
KR20210127215A (ko) 2021-10-21
EP3923973A1 (en) 2021-12-22
EA202192241A1 (ru) 2022-03-11
BR112021015428A2 (pt) 2022-02-15
AU2020220651A1 (en) 2021-09-09
WO2020165664A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
DK3521282T3 (da) Quinazolinderivater anvendt til behandling af hiv
DK3393655T3 (da) Fenfluramin-sammensætninger og fremgangsmåder til fremstilling af samme
DK3307299T3 (da) Kombinationssammensætninger til behandling af lidelser krævende fjernelse eller ødelæggelse af uønskede celleformeringer
DK3524255T3 (da) Sammensætning til behandling af acne
DK3081263T3 (da) Sammensætninger og redskaber til behandling af glaukom
DK3606929T3 (da) Beta-nicotinat-ester-nukleotider og fremgangsmåder til fremstilling af samme
DK3280408T3 (da) Fremgangsmåde til fremstilling af dicycloplatin
DK3261661T3 (da) Menotropin til behandling af infertilitet
DK3459543T3 (da) Carbamatforbindelse til forebyggelse eller behandling af fibromyalgi
GB201808617D0 (en) Scaffold modification
DK3573620T3 (da) Sammensætninger til behandling af hypertension
DK3478713T3 (da) Sammensætninger til behandling af amyloidose
DK3302573T3 (da) Sammensætning til behandlingen af hjernelæsioner
DK3355699T3 (da) Bicyklisk forbindelse og anvendelse deraf til inhibering af suv39h2
DK3638293T3 (da) Sammensætninger til behandling af cancer
DK3459542T3 (da) Anvendelse af carbamatforbindelse til forebyggelse eller behandling af trigeminusneuralgi
DK3923973T3 (da) Langtidsvirkende g-csf til forebyggelse af neutropeni eller reduktion af varigheden af neutropeni
DK3620452T3 (da) Fremgangsmåde til fremstilling af lenvatinib
DK3709996T3 (da) Coumarin-derivat til behandling eller forebyggelse af en celleproliferativ lidelse
GB201804366D0 (en) Scaffold
DK3490970T3 (da) Sammensætninger til behandling af lungefibrose
DK3236961T3 (da) Farmaceutisk sammensætning til forebyggelse eller behandling af cancer
DK3886799T3 (da) Sammensætninger til behandlingen af hårtab
DK3763212T3 (da) Artropoda-afvisende sammensætning
GB201819609D0 (en) Scaffold